Progress in research & development of interferon-antibody conjugates / 中国生化药物杂志
Chinese Journal of Biochemical Pharmaceutics
;
(6): 19-24, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-496392
ABSTRACT
Interferon ( IFN) kills tumor throughdirect tumor killing, stimulating immune response to tumor cells by activating the immune system and inhibiting tumor angiogenesis.However, its clinical application has been restrained by the deficiencies such as short half-life and severe side effects.IFN-antibody fusion can bring IFN to the vicinity of tumors using tumor specific antibody, while reducing the concentration of IFN in the rest parts of the body.Thus, system toxicity caused by IFN can be significantly lessened.We herein summarized the research and development of preclinical antibody-interferon conjugates and provide new thought on the development of IFN or antibody based fusion proteins.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Biochemical Pharmaceutics
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS